William D. Bradley

1.4k total citations
15 papers, 822 citations indexed

About

William D. Bradley is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, William D. Bradley has authored 15 papers receiving a total of 822 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 5 papers in Oncology and 4 papers in Cell Biology. Recurrent topics in William D. Bradley's work include Cell Adhesion Molecules Research (4 papers), DNA Repair Mechanisms (3 papers) and Cellular Mechanics and Interactions (3 papers). William D. Bradley is often cited by papers focused on Cell Adhesion Molecules Research (4 papers), DNA Repair Mechanisms (3 papers) and Cellular Mechanics and Interactions (3 papers). William D. Bradley collaborates with scholars based in United States, Russia and Bulgaria. William D. Bradley's co-authors include Anthony J. Koleske, Jeffrey Settleman, Samuel E. Hernández, Charles A. Greer, Shannon L. Gourley, Jane R. Taylor, Kathryn Packman, Scott Kopetz, Fei Su and Hong Yang and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Journal of Neuroscience.

In The Last Decade

William D. Bradley

15 papers receiving 813 citations

Peers

Countries citing papers authored by William D. Bradley

Since Specialization

Citations

This map shows the geographic impact of William D. Bradley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William D. Bradley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William D. Bradley more than expected).

Fields of papers citing papers by William D. Bradley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William D. Bradley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William D. Bradley. The network helps show where William D. Bradley may publish in the future.

Co-authorship network of co-authors of William D. Bradley

This figure shows the co-authorship network connecting the top 25 collaborators of William D. Bradley. A scholar is included among the top collaborators of William D. Bradley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William D. Bradley. William D. Bradley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Phase 1 results of CYT-0851, a monocarboxylate transporter (MCT) inhibitor, in combination with capecitabine (cape) or gemcitabine (gem) in advanced solid tumors. 2023 ·Journal of Clinical Oncology ·Ryan C. Lynch, Pamela N. Münster, Gerald S. Falchook, Monika L. Burness, Timothy A. Yap, Geoffrey I. Shapiro, David R. Spigel, Manish R. Patel, Kathleen N. Moore, Dejan Juric, Susan Doleman, William D. Bradley, (unknown), Judson M. Englert, Markus F. Renschler, Nina Beri	4
2	Abstract LB_A13: Phase 1 dose expansion results of CYT-0851, a monocarboxylate transporter (MCT) inhibitor, in combination with capecitabine (cape) in platinum-resistant ovarian cancer 2023 ·Molecular Cancer Therapeutics ·Elizabeth M. Swisher, Gerald S. Falchook, Pamela N. Münster, Nina Beri, Kathleen N. Moore, Timothy A. Yap, David R. Spigel, Susan Doleman, William D. Bradley, (unknown), Markus F. Renschler, Ryan C. Lynch	2
3	Phase 1 results of a phase 1/2 trial of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination, in patients with advanced solid and hematologic cancers. 2022 ·Journal of Clinical Oncology ·Ryan C. Lynch, Pamela N. Münster, Ranjana H. Advani, Mehdi Hamadani, David R. Spigel, Gerald S. Falchook, Manish R. Patel, David S. Siegel, Nina Beri, Grzegorz S. Nowakowski, Neil Palmisiano, Monika L. Burness, Kathleen N. Moore, Geoffrey I. Shapiro, Dejan Juric, William D. Bradley, (unknown), Markus F. Renschler, Judson M. Englert, Timothy A. Yap	4
4	First-in-human phase I/II study of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination in patients with advanced solid and hematologic cancers. 2021 ·Journal of Clinical Oncology ·Ryan C. Lynch, Johanna C. Bendell, Ranjana H. Advani, Gerald S. Falchook, Pamela N. Münster, Manish R. Patel, Martin Gutierrez, Monika L. Burness, Neil Palmisiano, Mehdi Hamadani, William D. Bradley, (unknown), Susan Doleman, Markus F. Renschler, Judson M. Englert, Timothy A. Yap	8
5	Design, Synthesis, and Pharmacological Evaluation of Second Generation EZH2 Inhibitors with Long Residence Time 2020 ·ACS Medicinal Chemistry Letters ·(unknown), Alexandre Côté, Shilpi Arora, Ludivine Moine, Victor Gehling, Jehrod Brenneman, Nico Cantone, Jacob I. Stuckey, (unknown), Ashwin Ramakrishnan, (unknown), William D. Bradley, James E. Audia, Richard Cummings, Robert J. Sims, Patrick Trojer, Julian Levell	27
6	A phase 1 study of CPI-1205, a small molecule inhibitor of EZH2, preliminary safety in patients with B-cell lymphomas 2018 ·Annals of Oncology ·Wael A. Harb, Jeremy S. Abramson, Matthew A. Lunning, André Goy, Kami J. Maddocks, Claudia Lebedinsky, Adrian M. Senderowicz, Patrick Trojer, William D. Bradley, Ian W. Flinn	24
7	Direct Interactions with the Integrin β1 Cytoplasmic Tail Activate the Abl2/Arg Kinase 2015 ·Journal of Biological Chemistry ·(unknown), William D. Bradley, David S. Harburger, Maddy Parsons, David Calderwood, Anthony J. Koleske	37
8	Integrin β1 Signals through Arg to Regulate Postnatal Dendritic Arborization, Synapse Density, and Behavior 2012 ·Journal of Neuroscience ·(unknown), William D. Bradley, Shannon L. Gourley, Yu‐Chih Lin, (unknown), Louis F. Reichardt, Charles A. Greer, Jane R. Taylor, Anthony J. Koleske	94
9	Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer 2011 ·Cancer Research ·Hong Yang, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, William D. Bradley, Richard J. Lee, Kathleen Schostack, Mary Ellen Simcox, Scott Kopetz, David Heimbrook, Brian Lestini, Gideon Bollag, Fei Su	170
10	The emerging role of the intestine in metabolic diseases 2011 ·Archives of Physiology and Biochemistry ·William D. Bradley, Catherine Zwingelstein, Cristina M. Rondinone	13
11	Regulation of cell migration and morphogenesis by Abl-family kinases: emerging mechanisms and physiological contexts 2009 ·Journal of Cell Science ·William D. Bradley, Anthony J. Koleske	144
12	Inhibition of Rho via Arg and p190RhoGAP in the Postnatal Mouse Hippocampus Regulates Dendritic Spine Maturation, Synapse and Dendrite Stability, and Behavior 2007 ·Journal of Neuroscience ·(unknown), Aaron S. Eisman, Shannon L. Gourley, William D. Bradley, (unknown), Jeffrey Settleman, Jane R. Taylor, Charles A. Greer, Anne Williamson, Anthony J. Koleske	105
13	The Abl-related Gene Tyrosine Kinase Acts through p190RhoGAP to Inhibit Actomyosin Contractility and Regulate Focal Adhesion Dynamics upon Adhesion to Fibronectin 2007 ·Molecular Biology of the Cell ·Justin G. Peacock, Ann L. Miller, William D. Bradley, Olga Rodriguez, Donna J. Webb, Anthony J. Koleske	69
14	Integrin Signaling through Arg Activates p190RhoGAP by Promoting Its Binding to p120RasGAP and Recruitment to the Membrane 2006 ·Molecular Biology of the Cell ·William D. Bradley, Samuel E. Hernández, Jeffrey Settleman, Anthony J. Koleske	101
15	Optimizing the Interfacial Binding and Activity of a Bacterial Phosphatidylinositol-specific Phospholipase C 2003 ·Journal of Biological Chemistry ·Jianwen A. Feng, William D. Bradley, Mary F. Roberts	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact